{"entity":{"type":"insider","cik":"0001792575","url":"/insider/0001792575","json_url":"/insider/0001792575.json","name":"InvOpps IV, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":4,"n_filings":2,"first":"2019-11-06","last":"2020-05-21","span_basis":"filed_date"},"name_variants":[{"name":"InvOpps IV, L.P.","source":"filing","n_filings":2,"first_seen":"2019-11-06","last_seen":"2020-05-21"}],"transactions":[{"id":3032889,"accession":"0000899243-20-013881","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-013881","line_url":"/filing/0000899243-20-013881#line-2","is_derivative":false,"issuer_cik":"0001053891","issuer_name":"Oyster Point Pharma, Inc.","issuer_ticker":"OYST","issuer_name_source":null,"issuer_url":"/issuer/0001053891","owner_cik":null,"owner_name":"LAINOVIC SACHA; InvOpps IV US, L.P.; InvOpps IV, L.P.; InvOpps GP IV, L.L.C.","owner_display_name":"LAINOVIC SACHA","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":119393.0,"shares_display":"119,393","price_per_share":28.0,"price_display":"28.00","price_state":"stated","total_value":3343004.0,"total_display":"3,343,004.00","total_whole":"3,343,004","shares_owned_after":1850818.0,"shares_owned_after_display":"1,850,818","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-19","filed_date":"2020-05-21","scope":"insider"},{"id":3032885,"accession":"0000899243-20-013881","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-013881","line_url":"/filing/0000899243-20-013881#line-1","is_derivative":false,"issuer_cik":"0001053891","issuer_name":"Oyster Point Pharma, Inc.","issuer_ticker":"OYST","issuer_name_source":null,"issuer_url":"/issuer/0001053891","owner_cik":null,"owner_name":"LAINOVIC SACHA; InvOpps IV US, L.P.; InvOpps IV, L.P.; InvOpps GP IV, L.L.C.","owner_display_name":"LAINOVIC SACHA","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":59178.0,"shares_display":"59,178","price_per_share":28.0,"price_display":"28.00","price_state":"stated","total_value":1656984.0,"total_display":"1,656,984.00","total_whole":"1,656,984","shares_owned_after":917768.0,"shares_owned_after_display":"917,768","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-19","filed_date":"2020-05-21","scope":"insider"},{"id":8376778,"accession":"0000899243-19-026771","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-026771","line_url":"/filing/0000899243-19-026771#line-4","is_derivative":false,"issuer_cik":"0001053891","issuer_name":"Oyster Point Pharma, Inc.","issuer_ticker":"OYST","issuer_name_source":null,"issuer_url":"/issuer/0001053891","owner_cik":null,"owner_name":"InvOpps IV US, L.P.; InvOpps GP IV, L.L.C.; LAINOVIC SACHA; InvOpps IV, L.P.","owner_display_name":"InvOpps IV US, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":501375.0,"shares_display":"501,375","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":8022000.0,"total_display":"8,022,000.00","total_whole":"8,022,000","shares_owned_after":1731425.0,"shares_owned_after_display":"1,731,425","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-04","filed_date":"2019-11-06","scope":"insider"},{"id":8376773,"accession":"0000899243-19-026771","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-19-026771","line_url":"/filing/0000899243-19-026771#line-3","is_derivative":false,"issuer_cik":"0001053891","issuer_name":"Oyster Point Pharma, Inc.","issuer_ticker":"OYST","issuer_name_source":null,"issuer_url":"/issuer/0001053891","owner_cik":null,"owner_name":"InvOpps IV US, L.P.; InvOpps GP IV, L.L.C.; LAINOVIC SACHA; InvOpps IV, L.P.","owner_display_name":"InvOpps IV US, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":248625.0,"shares_display":"248,625","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":3978000.0,"total_display":"3,978,000.00","total_whole":"3,978,000","shares_owned_after":858590.0,"shares_owned_after_display":"858,590","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-04","filed_date":"2019-11-06","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001720725","name":"Oyster Point Pharma, Inc.","url":"/issuer/0001720725","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2019-11-06","last_seen":"2020-05-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001792575","retrieved_at":"2026-08-22T05:12:55+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}